Blood cell substitute to get priority review

EVANSTON - Northfield Laboratories Inc. said Tuesday that the U.S. Food and Drug Administration has accepted for filing its Biologics License Application for PolyHeme, the company's investigative human hemoglobin-based red cell substitute for the treatment of life-threatening red blood cell loss when an oxygen-carrying fluid is required and red blood cells are not available. In addition, the FDA has designated the submission for priority review, with a review goal date of April 30.